Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 Next >
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
From AstraZeneca
Via Business Wire
Tickers AZN
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
From AstraZeneca
Via Business Wire
Tickers AZN
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
From AstraZeneca
Via Business Wire
Tickers AZN
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
From AstraZeneca
Via Business Wire
Tickers AZN
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
From AstraZeneca
Via Business Wire
Tickers AZN
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
From AstraZeneca
Via Business Wire
Tickers AZN
PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
From AstraZeneca
Via Business Wire
Tickers AZN
Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
From AstraZeneca
Via Business Wire
Tickers AZN
CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
From AstraZeneca
Via Business Wire
Tickers AZN
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
From AstraZeneca
Via Business Wire
Tickers AZN
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.